Kaftrio approved for eligible children with CF, ages 2-5, in EU cysticfibrosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cysticfibrosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
Vertex Pharmaceuticals: Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Vertex Pharma (VRTX) Announces EMA Validation for Marketing Authorization Application Extension for KAFTRIO in Combination With Ivacaftor streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
-Application to add ~200 non-F508del CFTR mutations to the KAFTRIO® license-
-If approved, ~2,800 people with cystic fibrosis in the European Union ages 2 and above could receive a medicine that.
Patients with rheumatic disease who continued TNF blockers during their pregnancy did not have an increased risk of worse fetal and maternal outcomes and had a lower risk of severe infection.